Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Lilly locks in 5-program R&D pact with China’s Haisco worth up to $3B, but targets unclear

Lilly locks in 5-program R&D pact with China’s Haisco worth up to $3B, but targets unclear

  • June 1, 2026

Within hours of securing a gastrointestinal drug from Korea’s Hanmi Pharma, Eli Lilly has ramped up the biobucks for a wider-ranging pact with China’s Haisco Pharmaceutical.

Leave A Comment

Fields (*) Mark are Required